Meet our Management

Robert Wessman

Portrait of Robert Wessman

Robert Wessman became the Executive Chairman of Alvogen in July 2009 and is now both the Chairman & CEO of the group. Wessman was CEO of Actavis Group, one of the largest generic pharmaceutical companies in the world for nine years.

A business graduate and former lecturer at the University of Iceland, Wessman began his career at the Icelandic shipping company Samskip where he quickly advanced to the post of CEO for Samskip in Germany. In 1999, he became President and CEO of Delta in 1999, which later formed Actavis through a merger with Pharmaco.

Wessman arrived at the helm of Actavis having built himself a solid reputation in Europe as a fast thinking and ambitious business man. From the start, he succeeded in turning his small Icelandic company into one of the leading global companies in the generic industry. In only seven years, the company grew from an annual turnover of EUR 57 million to more than EUR 1.6 billion, with a market capitalization of approximately EUR 3 billion.

Wessman is known for his clear focus and his ability to successfully combine operational efficiency and external growth through strategic acquisitions and the integration of over 30 companies. His achievements have made him the subject of a Harvard Business School Case Study published in May 2008, titled “Robert Wessman and the Actavis Winning Formula”.

Alvogen Americas Senior Management

William Hill

EVP – US Commercial Operations
Portrait of William Hill

William Hill brings 25 years of brand and generic pharmaceuticals experience in roles of increasing responsibility that includes multiple therapeutic areas and all classes of trade. Mr. Hill comes to Alvogen from Dr. Reddy’s Laboratories, where he led North American sales and commercial operations. He was promoted to VP Sales after a successful tenure in National Accounts, highlighted by several Paragraph 4 product launches and Dr. Reddy’s entry into the top ten generic company status. 

Prior to Dr. Reddy’s, Mr. Hill served in sales and management roles URL, Dey, Warner Chilcott, Endo and Sandoz.

Bill is married (wife Christy) and resides with his three children (Quentin 13, Jaden 11, Maya 9) in Lake Norman, NC.

Lisa Graver

EVP – Strategic Operations
Portrait of Lisa Graver

Lisa Graver drives the execution of critical business and technical projects and processes throughout the Alvogen Americas business. Ms. Graver leads R&D, Regulatory Affairs, Portfolio Management, and US Legal including all US Intellectual Property strategy and litigation. Ms. Graver applies more than 15 years experience representing pharmaceutical companies in patent litigation and counseling. 

Her achievements include successful results while in private practice, formerly with Kirkland & Ellis, and then as the in-house counsel for generic pharmaceutical companies Alpharma and Actavis.

Ms. Graver holds a juris doctorate, cum laude, from Case Western Reserve University School of Law. She earned her undergraduate degree, with honors, in biology and biological anthropology from Lakehead University.

Andrea Johnson

Vice President - Sales Operations
Portrait of Andrea Johnson

Andrea Johnson has more than 20 years’ experience in both generic and branded pharmaceuticals. Her knowledge and experience in Customer Focus, Operational Effectiveness, Teambuilding and Process Improvements (Kaizen and Lean Six Sigma) allows her to effectively lead and manage Alvogen’s customer service, credit & collections and contracting & pricing operations.

Prior to joining Alvogen, Mrs. Johnson was the Senior Director of Pricing & Contracts and Financial Sales Operations at Actavis Inc., where she was able to successfully lead significant operational improvements resulting in millions of dollars in savings.

Mrs. Johnson has held roles of increasing responsibility throughout her career including successful positions at Johnson & Johnson Healthcare Systems, Pfizer and Alpharma.

Dr. Mayank Joshi

Vice Precident - Research and Development
Portrait of Dr. Mayank Joshi

Dr. Mayank Joshi, Vice President of Research and Development, leads both internal and external scientific development teams responsible for ensuring successful execution of product development, product transfers, scale-up, process engineering, facility and equipment qualification and all validation tasks to support revenue and profitability growth for Alvogen's US organization. He is also driving the development of first to file ANDAs in the development pipeline, and conducting technical due diligence for potential third party partners identified by business development.

Dr Joshi has extensive experience of about 20 years in the development and commercialization of modified release products. Prior to joining Alvogen in 2012, Dr. Joshi was Director Formulations (R&D) at Actavis (Watson Inc), Senior Manager of Full Formulation Development at Apotex Inc, and Group Leader at Alembic, among other roles. Dr. Joshi has a Ph.D. in Novel Drug Delivery Systems from the Maharaja Sayajirao University of Baroda, India. He has been principal inventor of numerous patents and have published several scientific papers in respected journals around the world.

Steve Kondracki

Vice President - Supply Chain

Delivering more than 30 years of brand and generic pharmaceuticals supply chain management experience, Steve Kondracki leads Alvogen strategic planning for product supply and distribution.

Throughout his career, Mr. Kondracki, a certified Lean Six Sigma Black Belt, has successfully directed all aspects of pharmaceutical supply chain management for both regional and international operations. 

Prior to joining Alvogen, Mr. Kondracki led supply chain operations for companies including Alpharma, Barr and Wockhardt. He earned an honors degree in Management Science from Rutgers University.

Entrepreneur Of The Year

Alvogen has been honored by Ernst & Young for rethinking the ways businesses grow and thrive.